New hope for lymphoma patients who fail standard therapies
NCT ID NCT07525817
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called pirtobrutinib in 40 people with mature B-cell lymphoma whose cancer has worsened or who cannot tolerate other BTK inhibitor drugs. Participants take one pill daily. Researchers will measure how many patients respond, how long the response lasts, and track side effects. The study is not yet recruiting and will take place at 8 centers in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pirtobrutinib
- What this could lead to
- If successful, this could provide a new treatment option for patients with B-cell lymphoma who have stopped responding to other BTK inhibitors.
- What could go wrong
- This is a small, early real-world study with only 40 participants. It may not show strong enough results or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATURE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, 130021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.